Evidence map›Paper›PMID 26553749›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2016

Dysregulation of miR-212 Promotes Castration Resistance through hnRNPH1-Mediated Regulation of AR and AR-V7: Implications for Racial Disparity of Prostate Cancer.

Yijun Yang, Dingwu Jia, Hogyoung Kim, Zakaria Y Abd Elmageed, Amrita Datta, Rodney Davis, Sudesh Srivastav, Krzysztof Moroz, Byron E Crawford, Krishnarao Moparty and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 84 citations in OpenAlex.

  1. Article
  2. Review
  3. HNRNPH1-mediated splicing events regulatebioRxiv : the preprint server for biology · 2025
    Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Yijun YangDepartment of Urology, Tulane University School of Medicine, New Orleans, Louisiana.
Dingwu JiaDepartment of Urology, Tulane University School of Medicine, New Orleans, Louisiana.
Hogyoung KimDepartment of Urology, Tulane University School of Medicine, New Orleans, Louisiana.
Zakaria Y Abd ElmageedDepartment of Urology, Tulane University School of Medicine, New Orleans, Louisiana.
Amrita DattaDepartment of Urology, Tulane University School of Medicine, New Orleans, Louisiana.
Rodney DavisDepartment of Urology, Tulane University School of Medicine, New Orleans, Louisiana.
Sudesh SrivastavDepartment of Biostatistics, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.
Krzysztof MorozDepartment of Pathology, Tulane University School of Medicine, New Orleans, Louisiana. Tulane Cancer Center, Tulane University School of Medicine, New Orleans, Louisiana.
Byron E CrawfordDepartment of Pathology, Tulane University School of Medicine, New Orleans, Louisiana.
Krishnarao MopartyDepartment of Urology, Tulane University School of Medicine, New Orleans, Louisiana. Division of Urology, Southeast Louisiana Veterans Health Care System, New Orleans, Louisiana.
Raju ThomasDepartment of Urology, Tulane University School of Medicine, New Orleans, Louisiana. Tulane Cancer Center, Tulane University School of Medicine, New Orleans, Louisiana.
Robert S HudsonLaboratory of Human Carcinogenesis, National Cancer Institute, NIH, Bethesda, Maryland.
Stefan AmbsLaboratory of Human Carcinogenesis, National Cancer Institute, NIH, Bethesda, Maryland.
Asim B Abdel-MageedDepartment of Urology, Tulane University School of Medicine, New Orleans, Louisiana. Tulane Cancer Center, Tulane University School of Medicine, New Orleans, Louisiana. Department of Pharmacology, Tulane University School of Medicine, New Orleans, Louisiana. amageed@tulane.edu.
Tulane University · USNational Cancer Institute · US

Funding

The Molecular Profile of Prostate Tumors in African-American MenZIABC010624 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI AMBS, STEFAN · 2009 to 2025
$8.0M
Estrogen-ERbeta Axis In Disparity of Prostate CancerU01CA149204 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI ABDEL-MAGEED, ASIM B · 2011 to 2015
$1.4M
The Molecular Profile of Prostate Tumors in African-American MenZ01BC010624 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI AMBS, STEFAN · 2005 to 2008
$1.1M
Intramural NIH HHS Z01 BC010624NCI NIH HHS U01 CA149204
6 · The paper itself

Abstract

purposeThe causes of disproportionate incidence and mortality of prostate cancer among African Americans (AA) remain elusive. The purpose of this study was to investigate the mechanistic role and assess clinical utility of the splicing factor heterogeneous nuclear ribonucleoprotein H1 (hnRNP H1) in prostate cancer progression among AA men. EXPERIMENTAL

designWe employed an unbiased functional genomics approach coupled with suppressive subtractive hybridization (SSH) and custom cDNA microarrays to identify differentially expressed genes in microdissected tumors procured from age- and tumor grade-matched AA and Caucasian American (CA) men. Validation analysis was performed in independent cohorts and tissue microarrays. The underlying mechanisms of hnRNPH1 regulation and its impact on androgen receptor (AR) expression and tumor progression were explored.

resultsAberrant coexpression of AR and hnRNPH1 and downregulation of miR-212 were detected in prostate tumors and correlate with disease progression in AA men compared with CA men. Ectopic expression of miR-212 mimics downregulated hnRNPH1 transcripts, which in turn reduced expression of AR and its splice variant AR-V7 (or AR3) in prostate cancer cells. hnRNPH1 physically interacts with AR and steroid receptor coactivator-3 (SRC-3) and primes activation of androgen-regulated genes in a ligand-dependent and independent manner. siRNA silencing of hnRNPH1 sensitized prostate cancer cells to bicalutamide and inhibited prostate tumorigenesis in vivo

conclusionsOur findings define novel roles for hnRNPH1 as a putative oncogene, splicing factor, and an auxiliary AR coregulator. Targeted disruption of the hnRNPH1-AR axis may have therapeutic implications to improve clinical outcomes in patients with advanced prostate cancer, especially among AA men.

Indexed as

Gene Expression Regulation, NeoplasticAlternative SplicingAndrogensAnilidesAntineoplastic AgentsCell Line, TumorCell ProliferationCluster AnalysisDisease ProgressionDrug Resistance, NeoplasmGene Expression ProfilingGene SilencingHeterogeneous-Nuclear Ribonucleoprotein Group F-HHumansMaleMicroRNAsAndrogensAnilidesAntineoplastic AgentsbicalutamideHeterogeneous-Nuclear Ribonucleoprotein Group F-HMicroRNAsMIRN212 microRNA, humanNitrilesNuclear Receptor Coactivator 3Receptors, AndrogenTosyl Compounds

Identifiers

PMID26553749
PMCPMC7472565
OpenAlexW2169941515

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.